Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metastatic Testicular Germ Cell Tumor in a Patient With Neurofibromatosis Type 1: Treatment With Trametinib Based on <i>NF1</i> Gene Mutation.

IJU case reports·2026
Same author

AI-Based Analysis of Tumor-Infiltrating Lymphocytes and Homologous Recombination in Ovarian Cancer: JGOG3025-A1 Study.

Cancer science·2026
Same author

Nationwide survey of hereditary breast and ovarian cancer-related clinical practice in gynecologic oncology in Japan: a joint study by the Japan Society of Gynecologic Oncology (JSGO) and the Japan Society of Obstetrics and Gynecology (JSOG).

Journal of gynecologic oncology·2026
Same author

Isolated Subcarinal Lymph Node Recurrence 24 Years After Treatment for Primary Tracheal Adenoid Cystic Carcinoma.

Respirology case reports·2026
Same author

TANC1::HTRA1 and KPNA4::WWTR1 fusions in non-vestibular intracranial schwannomas.

Acta neuropathologica·2026
Same author

Genomic Profiling of Cancerous Areas, Dysplasia, and Background Mucosa in Ulcerative Colitis-associated Colorectal Cancer.

Anticancer research·2026

Related Experiment Video

Updated: Sep 25, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K

Tumor mutational burden measurement using comprehensive genomic profiling assay.

Hidenori Kage1, Shinji Kohsaka2, Kenji Tatsuno3

  • 1Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University Tokyo, Tokyo, Japan.

Japanese Journal of Clinical Oncology
|April 28, 2022
PubMed
Summary

High tumor mutational burden (TMB) predicts response to immunotherapy. The Todai OncoPanel assay, particularly version 6, accurately measures TMB, with target TMB showing promise for clinical use.

Keywords:
cancer genegenomicsimmune checkpoint inhibitorsmutationtumor mutational burden

More Related Videos

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.8K
Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing
11:02

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 18, 2013

19.5K

Related Experiment Videos

Last Updated: Sep 25, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.8K
Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing
11:02

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 18, 2013

19.5K

Area of Science:

  • Oncology
  • Genomics
  • Immunotherapy

Background:

  • High tumor mutational burden (TMB) is associated with better response to immune checkpoint inhibitors.
  • Optimal methods for calculating TMB using comprehensive genomic profiling (CGP) assays are not well-established.

Purpose of the Study:

  • To evaluate the accuracy of TMB calculation using two versions of the Todai OncoPanel DNA assay.
  • To compare TMB measurements with whole exome sequencing (WES) and assess their correlation with clinical response in lung cancer patients.

Main Methods:

  • Todai OncoPanel DNA versions 3 and 6 were used to calculate TMB via three methods: target TMB, all coding TMB, and non-synonymous coding TMB.
  • TMB values were compared against WES-derived TMB.
  • Lung cancer patients treated with anti-PD-1/PD-L1 therapy were analyzed for TMB and PD-L1 expression.

Main Results:

  • Todai OncoPanel v6 demonstrated higher accuracy (91-96%) compared to v3 (71%) when correlated with WES TMB.
  • Patients with partial response or stable disease exhibited significantly higher non-synonymous coding TMB and PD-L1 expression than those with progressive disease.
  • A trend towards higher target TMB was observed in patients with better clinical outcomes.

Conclusions:

  • Improvements in Todai OncoPanel (v6), including increased gene targets and limited intronic regions, enhance TMB measurement accuracy.
  • Target TMB calculation may be the preferred method for assessing TMB in clinical settings.
  • Accurate TMB assessment is crucial for predicting immunotherapy response.